Whalesbook
Nayi Dawa, Naya Market?
Dekho, US Food and Drug Administration (FDA) ne Lupin ki generic Sodium Sulfate, Magnesium Sulfate, aur Potassium Chloride tablets ko approve kar diya hai. Yeh wahi drug hai jo Sutab therapy jaise kaam karti hai. Sabse achhi baat yeh hai ki Lupin first-to-file thi, toh isse U.S. mein 180 din ki generic exclusivity milegi. Isse company ko market share capture karne mein help milegi.
Reference drug ne March 2026 tak $132.8 million ka U.S. sales kiya tha. Yeh ek accha revenue target hai. Ab dekhte hain ki company apni Nagpur facility mein production scale kar paati hai aur is market mein enter kar paati hai jahan abhi bade players hain.
Regulatory Tension?
Sab theek chal raha tha, par Lupin abhi bhi regulatory attention mein hai. April 2026 mein, unki Somerset, New Jersey wali manufacturing site par FDA inspection mein 3 observations mili theen. Yeh violations Food, Drug, and Cosmetic Act ke hain. Aisi cheezein aage jaakar new ANDA approvals ko delay kar sakti hain agar quality control mein problems solve nahi hui toh.
Company bolti hai ki woh Current Good Manufacturing Practice (CGMP) standards follow kar rahe hain, par baar baar warnings milna investors ke liye chinta ka vishay hai.
Valuation aur Sector View
Lupin ka P/E ratio around 19.5x se 22.9x hai, jo domestic peers ke comparison mein moderate hai. Sun Pharmaceutical Industries jaise companies ka P/E 35x se bhi upar hai. Lupin ka stock pichhle ek saal mein 15% se zyada badha hai, jabki analysts ne bhi 'Strong Buy' se 'Buy' rating kar di hai.
Kya Hai Risk?
Sabse bada risk hai U.S. mein growth ki sustainability. Lupin ka 40% revenue North America se aata hai. Agar manufacturing sites par koi problem hui toh earnings par bahut impact padega.
Plus, generic colonoscopy prep market mein bohot competition hai. Miralax, Suprep, aur Clenpiq jaise drugs already popular hain. Lupin ko sirf 180 din ki exclusivity par depend nahi rehna hai, balki high-volume production aur quality maintain karni hogi.
Company ka target hai FY2027 tak U.S. revenue $1 billion se upar rakhna, lekin iske liye R&D aur quality compliance dono par focus karna hoga.